2,46 Mb - GuÃaSalud
2,46 Mb - GuÃaSalud
2,46 Mb - GuÃaSalud
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
185. de GG. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised<br />
trial in general practice. Collaborative Group of the Primary Prevention Project. Lancet.<br />
2001;357(9250):89-95.<br />
186. Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, et al. A randomized<br />
trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N<br />
Engl J Med. 2005;352(13):1293-304.<br />
187. Vijan S, Hayward RA. Pharmacologic lipid-lowering therapy in type 2 diabetes mellitus:<br />
background paper for the American College of Physicians. Ann Intern Med.<br />
2004;140(8):650-8.<br />
188. Costa J, Borges M, David C, Vaz CA. Efficacy of lipid lowering drug treatment for diabetic<br />
and non-diabetic patients: meta-analysis of randomised controlled trials. BMJ.<br />
2006;332(7550):1115-24.<br />
189. Allemann S, Diem P, Egger M, Christ ER, Stettler C. Fibrates in the prevention of cardiovascular<br />
disease in patients with type 2 diabetes mellitus: meta-analysis of randomised<br />
controlled trials. Curr Med Res Opin. 2006;22(3):617-23.<br />
190. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et<br />
al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in<br />
the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebocontrolled<br />
trial. Lancet. 2004;364(9435):685-96.<br />
191. Knopp RH, d’Emden M, Smilde JG, Pocock SJ. Efficacy and safety of atorvastatin in the<br />
prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin<br />
Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes<br />
mellitus (ASPEN). Diabetes Care. 2006;29(7):1478-85.<br />
192. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with<br />
type 2 diabetes mellitus (the FIELD study): randomised controlled trial. The Lancet.<br />
2005;366(9500):1849-61.<br />
193. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and<br />
safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056<br />
participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267-78.<br />
194. Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol. 2006;97(8A):52C-<br />
60C.<br />
195. Pfeffer MA, Keech A, Sacks FM, Cobbe SM, Tonkin A, Byington RP, et al. Safety and<br />
tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling (PPP)<br />
Project. Circulation. 2002;105(20):2341-6.<br />
196. Tight blood pressure control and risk of macrovascular and microvascular complications<br />
in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ.<br />
1998;317(7160):703-13.<br />
197. Schrier RW, Estacio RO, Esler A, Mehler P. Effects of aggressive blood pressure control in<br />
normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int.<br />
2002;61(3):1086-97.<br />
198. Turnbull F, Neal B, Algert C, Chalmers J, Chapman N, Cutler J, et al. Effects of different<br />
blood pressure-lowering regimens on major cardiovascular events in individuals with and<br />
without diabetes mellitus: results of prospectively designed overviews of randomized trials.<br />
Arch Intern Med. 2005;165(12):1410-9.<br />
CLINICAL PRACTICE GUIDELINE ON TYPE 2 DIABETES 173
Change language